Jun 2023 $1 M No. 5 Under $2 million 15
HDL Therapeutics, Inc.: Raise no. 5, Jun 2023 × Investors in this round 15 investors had bought by the notice of Jul 10, 2023: 15 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $7 M offered; $6 M still to sell
Smallest investment taken no minimum stated
What was sold equity, other: Series X Preferred Shares Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $277,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Bryan Brewer · Executive Officer Michael Matin · Executive Officer · Mr. Matin is the Chief Executive Officer and Secretary of the Issuer. Dane Andreeff · Director Gregg Sessa · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Michael Matin, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 10, 2023. Read the notice at the SEC .
equity SEC Feb 2021 $3 M No. 4 $2 to $10 million 31
HDL Therapeutics, Inc.: Raise no. 4, Feb 2021 × Investors in this round 31 investors had bought by the notice of Mar 4, 2021: 31 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $50 M offered; $47 M still to sell
Smallest investment taken no minimum stated
What was sold equity, other: Series E Preferred Stock Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Bryan Brewer · Executive Officer, Director · Dr. Brewer is the Chief Scientific Officer of the Issuer. Michael Matin · Executive Officer, Director · Mr. Matin is the Chief Executive Officer and Secretary of the Issuer. Dane Andreeff · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Frontier Solutions, LLC · Richmond, Virginia Sold in AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, IA, ID, IL, IN, KS, KY, LA, MA, MD, MI, MN, MO, MS, NC, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY Remarks in the notice On fees: “The Issuer has entered into a placement agent agreement with the persons named in Item 12 under which terms such persons will receive sales commissions and other fees based on the amount of approved sales. Such amounts are unknown at this time.”Signed by Michael Matin, Chief Executive Officer of the Issuer. Source: SEC Form D, newest notice filed Mar 4, 2021. Read the notice at the SEC .
equity SEC Sep 2019 $3 M No. 3 $2 to $10 million 34
HDL Therapeutics, Inc.: Raise no. 3, Sep 2019 × Investors in this round 34 investors had bought by the notice of Oct 3, 2019: 34 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity, other: Series D Preferred Stock Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Bryan Brewer · Executive Officer, Director · Dr. Brewer is the Chief Scientific Officer of the Issuer. Michael Matin · Executive Officer, Director · Mr. Matin is the Chief Executive Officer and Secretary of the Issuer. Dane Andreeff · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Michael Matin, Chief Executive Officer of the Issuer. Source: SEC Form D, newest notice filed Oct 3, 2019. Read the notice at the SEC .
equity SEC Aug 2016 $7 M No. 2 $2 to $10 million 57
HDL Therapeutics, Inc.: Raise no. 2, Aug 2016 × Investors in this round 57 investors had bought by the notice of May 10, 2017: 57 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $7 M of $12 M offered; $5 M still to sell
Smallest investment taken no minimum stated
What was sold equity, other: Series C Preferred Stock Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions $187,730
Finders' fees none
Paid to its own people $400,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Bryan Brewer · Executive Officer, Director · Dr. Brewer is the Chief Scientific Officer of the Issuer. Michael Matin · Executive Officer, Director · Mr. Matin is the Chief Executive Officer and Secretary of the Issuer. Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Morgan Stanley & Co. LLC · New York, New York Sold in all US states Frontier Solutions, LLC · Richmond, Virginia Sold in AL, AR, AZ, CA, CO, CT, DE, FL, GA, IL, IN, KY, LA, MA, MD, MN, NC, NJ, NY, OH, OR, PA, SC, TX, UT, VA, WA, WY Remarks in the notice On fees: “Commissions have been and will be paid to the persons named in Item 12 for introductions to investors.”On the use of proceeds: “The gross proceeds from the offering will be used for working capital, some of which will be used to pay the salaries of related persons named in Item 3.”Signed by Michael Matin, Chief Executive Officer of the Issuer. Source: SEC Form D and 1 amendment, newest notice filed May 10, 2017. Read the notice at the SEC .
equity SEC May 2014 $2 M No. 1 $2 to $10 million 14
HDL Therapeutics, Inc.: Raise no. 1, May 2014 × Investors in this round 14 investors had bought by the notice of Dec 31, 2014: 14 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $5 M offered; $3 M still to sell
Smallest investment taken no minimum stated
What was sold equity, other: Series B Preferred Stock Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $500,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Bryan Brewer · Executive Officer, Director · Dr. Brewer is the Chief Scientific Officer of the Issuer. Michael Matin · Executive Officer, Director · Mr. Matin is the Chief Executive Officer and Secretary of the Issuer. Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Michael Matin, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 31, 2014. Read the notice at the SEC .
equity SEC